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Myofibrillar myopathy (MFM) is a human disease that is characterized by focal myofibrillar destruction and
pathological cytoplasmic protein aggregations. In an extended German pedigree with a novel form of MFM char-
acterized by clinical features of a limb-girdle myopathy and morphological features of MFM, we identified a co-
segregating, heterozygous nonsense mutation (8130GrA; W2710X) in the filamin c gene (FLNC) on chromosome
7q32.1. The mutation is the first found in FLNC and is localized in the dimerization domain of filamin c. Functional
studies showed that, in the truncated mutant protein, this domain has a disturbed secondary structure that leads
to the inability to dimerize properly. As a consequence of this malfunction, the muscle fibers of our patients display
massive cytoplasmic aggregates containing filamin c and several Z-disk–associated and sarcolemmal proteins.
Myofibrillar myopathy (MFM) is a neuromuscular dis-
order, usually with adult onset and an autosomal domi-
nant inheritance pattern, that results in slowly progres-
sive weakening of limb muscles. MFM may lead to multi-
system involvement (eye, peripheral nerve, and heart),
and progressive cardiorespiratory complications are po-
tentially lethal (Goldfarb et al. 1998, 2004; Selcen and
Engel 2003; Ba¨r et al. 2005). Typically, skeletal-muscle
fibers of patients with MFM show Z-disk pathologies
in association with cytoplasmic accumulation of several
Z-disk and cytoplasmic proteins (Selcen and Engel
2004b). MFM is genetically heterogeneous. Thus far, four
genes have been associated with MFM: the genes en-
coding desmin (DES [MIM 125660]) (Goldfarb et al.
1998), myotilin (TTID [MIM 604103]) (Hauser et al.
2000; Selcen and Engel 2004a), Z-band alternatively
spliced PDZ motif-containing protein (LDB3 [MIM
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605906]) (Selcen and Engel 2005), and aB-crystallin
(CRYAB [MIM 123590]) (Vicart et al. 1998). However,
in the majority of patients with MFM, the presence of
mutations in these genes was excluded (Selcen and Engel
2005), indicating that mutations in other genes are also
causative of this disease.
In the present study, we have identified an extended
family of German origin with MFM, and we have ex-
cluded the involvement of the DES, TTID, and CRYAB
genes by haplotype analysis (data not shown). Informed
consent was obtained from all subjects (with approval
of the ethics committee of Ruhr-University Bochum
[#2221]). A total of 17 individuals (12 females and 5
males) were clinically affected. All patients presented
with slowly progressive skeletal-muscle weakness, be-
ginning in the lower extremities, which is compatible
with the clinical signs of limb-girdle muscular dystrophy
(LGMD). Eight of these patients (five females and three
males) had been examined clinically (table 1). Their weak-
ness started between the ages of 37 years and 57 years
and was more prominent proximally in seven patients,
whereas one patient (IV:16) had distal weakness of the
calf muscles only. Serum creatine kinase levels were mod-
erately elevated, up to 8-fold higher than the normal
upper limit. Four of the patients had respiratory symp-
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Figure 1 Immunohistochemical and ultrastructural analysis of aggregates in patient IV:3 from the pedigree with MFM. A, Several muscle
fibers with structural changes in the trichrome-stained sections, showing intracytoplasmic accumulation of the Z-disk–associated proteins filamin
c, myotilin, and desmin. Aggregates also show strong immunoreactivity for dystrophin and the sarcoglycans (as exemplified by g-sarcoglycan),
which are main components of the sarcolemmal dystrophin-glycoprotein complex (bar p 100 mm). B, Ultrastructural analysis of skeletal muscle,
showing multiple fibers displaying intermyofibrillar granulofilamentous protein aggregates (original magnification:# 20,000).
toms, and, in two of them (III:14 and III:16), nocturnal
ventilation was required. One affected individual (IV:3)
revealed findings compatible with cardiac involvement;
three of the eight patients had evidence of an additional
peripheral neuropathy (table 1). Individual IV:18 carries
the FLNC mutation but appears to be presymptomatic
as a result of his young age (28 years).
In patients III:18 and IV:3, the histological findings of
muscle biopsies from a clinically affected muscle were
typical of MFM. Many fibers showed structural changes
harboring amorphous, granular, or hyaline deposits best
recognized in trichrome-stained frozen sections (fig. 1A),
whereas some fibers showed vacuoles. Oxidative enzyme
activities (nicotinamide adenine dinucleotide dehydroge-
nase, succinic dehydrogenase, and cytochrome oxidase)
were sharply reduced in these abnormal fiber regions.
In each biopsy, increased internal nuclei, fiber splitting,
and isolated necrotic fibers were present. Serial trans-
verse cryostat sections (4 mm) of skeletal-muscle biopsies
from these patients were studied by immunofluorescence
assays with the use of monoclonal antibodies against fi-
lamin c (clone RR90; dilution 1:2) (van der Ven et al.
2000a), desmin (D33; 1:500 [DAKO]), myotilin (RSO34;
1:20), dystrophin (Dy8/6C5; 1:20), a-, b-, g-, and d-
sarcoglycan (Ad1/20A6, bSarc/SB1, 35DAG/21B5, d-
Sarc3/12C1; 1:100 [Novocastra]), and isotype-specific
secondary antibodies conjugated with fluorescein isothio-
cyanate or Cy2 (Southern Biotech). In each patient,
many abnormal fibers revealed a marked accumulation
of desmin, the histopathological hallmark of MFM, as
well as filamin c in massive aggregates. These aggregates
also showed strong immunoreactivity for the filamin c–
binding Z-disk protein myotilin, for the sarcolemma-
associated protein dystrophin, and for all sarcoglycans
(fig. 1A). Ultrastructural analysis of skeletal muscle from
patient IV:3 showed myofibrillar changes, including Z-
disk streaming and extensive nemaline-rod formation
(data not shown). As in MFMs that are due to hetero-
zygous desmin mutations (Schro¨der et al. 2003; Goldfarb
et al. 2004; Selcen and Engel 2004b; Ba¨r et al. 2005),
multiple fibers displayed intermyofibrillar and subsarco-
lemmal granulofilamentous protein aggregates (fig. 1B).
The dramatic mislocalization of filamin c in the muscle
fibers of our patients prompted us to perform haplotype
analysis, by use of microsatellite markers of the FLNC
gene region, and subsequently to screen the family with
MFM for mutations within the FLNC gene (MIM
102565). For haplotype and mutational analyses, ge-
nomic DNA was isolated from peripheral blood lympho-
cytes in accordance with standard procedures. Haplo-
type analysis of the candidate FLNC gene on chromo-
some 7q32.1 was performed with markers included in
the deCODE genetic map. Primer pairs were designed
with the OLIGO software (primer sequences are avail-
able on request). The primers were labeled with one of
four fluorophores: FAM, VIC, PET, or NED. PCR am-
plifications were performed in a T3 thermal cycler (Bio-
metra), and amplicons were separated on an ABI 3100
Genetic Analyzer (Applied Biosystems). The pedigree
was drawn with Cyrillic software, version 2.1 (Cherwell
Scientific Publishing), and haplotype analysis was per-
formed manually. Two-point LOD score calculationswere
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Table 2
Two-Point LOD Scores between Chromosome 7 Markers and the FLNC Locus
MARKER
LOD AT v p
.000 .001 .010 .050 .100 .150 .200 .300 .400
D7S487 2.458 2.453 2.407 2.207 1.964 1.727 1.492 1.014 .509
D7S2527 .299 .306 .355 .490 .546 .533 .479 .307 .124
D7S1873 2.310 2.306 2.274 2.117 1.894 1.655 1.410 .931 .470
D7S1822 2.417 2.415 2.393 2.262 2.050 1.807 1.548 1.020 .505
D7S680 2.871 2.865 2.808 2.549 2.218 1.885 1.553 .914 .360
D7S514 2.501 2.495 2.444 2.213 1.922 1.629 1.340 .787 .317
D7S635 4.879 4.870 4.786 4.408 3.920 3.416 2.897 1.827 .767
D7S2501 2.798 2.793 2.750 2.549 2.274 1.983 1.682 1.075 .499
D7S504 3.022 3.015 2.954 2.682 2.343 2.007 1.678 1.050 .483
D7S1875 4.286 4.278 4.203 3.865 3.434 2.994 2.547 1.640 .741
D7S530 1.822 1.817 1.771 1.575 1.352 1.143 .941 .550 .219
D7S2544 2.902 2.894 2.829 2.549 2.220 1.907 1.604 1.003 .419
D7S2519 1.460 1.458 1.437 1.338 1.202 1.057 .906 .597 .294
D7S2531 .294 .296 .312 .359 .375 .358 .315 .186 .056
D7S640 2.090 1.047 1.988 2.417 2.366 2.178 1.926 1.317 .639
Figure 2 A, Pedigree and genotypic analysis of the German family with autosomal dominant MFM segregating with FLNC. Marker haplotypes
on chromosome 7q31.33-7q32.3 that are linked to MFM are indicated by blackened bars. Blackened and unblackened symbols represent clinically
affected individuals and unaffected individuals, respectively; unblackened symbols with question marks represent individuals of undetermined disease
status. Presence () or absence () of the FLNC mutation in those individuals available for mutation analysis is indicated. N/A p not available
for genetic diagnosis. B, RFLP analysis of the 8130GrA mutation, by digestion of a PCR product with AluI. Undigested PCR product (120 bp)
corresponds to the G allele, and digested PCR product (98 bp  unverifiable 22 bp) corresponds to the A allele. C, Sequence chromatograms
demonstrating the heterozygous mutation (8130GrA; W2710X) found in affected family members (left) and the corresponding normal sequence
(right).
performed using the LINKAGE program package, with
the help of the LINKRUN program (T. F. Wienker, per-
sonal communication), under the assumption of auto-
somal dominant inheritance, equal male and female re-
combination rates, full penetrance, and a disease-allele
frequency of 0.0001. The National Center for Biotech-
nology Information (NCBI) Map Viewer and Ensembl
Genome Browser databases were used for localization
of the microsatellite marker loci and identification of
transcripts in the candidate region. The GDB Human
Genome Database was used for information about mi-
crosatellite markers and their primer sequences. Indeed,
haplotype analyses established linkage of the disease to
the FLNC locus (fig. 2A), with a maximum LOD score
of 4.879 ( ) at marker D7S635 (table 2).vp 0
Sequence analysis of FLNC included all 48 exons and
was performed on genomic DNA from individuals IV:3
and IV:16 of the present family, as well as on DNA from
four sporadic cases with similar clinical and morphologi-
cal features pointing to LGMD or MFM. Sequencing was
performed with an ABI 3100 Genetic Analyzer (Applied
Biosystems) by use of the BigDye Terminator v 1.1 Cycle
Sequencing kit (Applied Biosystems). Although no FLNC
mutations were found in the sporadic cases, a single
heterozygous nucleotide substitution (8130GrA), re-
sulting in a substitution of tryptophan at position 2710
by a stop codon (W2710X) (human FLNC [GenBank
accession number AF252549], human chromosome 7
clones containing FLNC [GenBank accession numbers
AC025594 and AC024952], and FLNC [accession num-
ber Q14315]), was identified in exon 48 in patients
IV:3 and IV:16 from the present family (fig. 2C).
To confirm cosegregation of the mutation with the
MFM disease phenotype, all available family members
and 110 control individuals were investigated for the
8130GrA mutation by RFLP analysis and/or direct se-
quencing. Since the mutation did not delete or intro-
duce a restriction site, a new AluI restriction site was
created in the mutant PCR product by use of a lower
primer with a single-nucleotide mismatch at the penult-
imate 3′ position (primer sequences are available on re-
quest). For restriction-enzyme digestion, the PCR prod-
uct was incubated with AluI, and the cleaved fragments
were separated on a 2% agarose gel and were visualized
by ethidium bromide staining (for details, see the legend
to fig. 2B). The 8130GrA mutation was detected in all
affected family members and was confirmed by direct
sequencing (fig. 2B). It was not observed in 220 control
chromosomes.
Recently, a large five-generation Spanish family with
LGMD, with clinical features similar to those seen in the
German family, was described (Gamez et al. 2001), and,
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Figure 3 Functional studies of the FLNC W2710X mutation. A, Circular dichroism spectrometry of filamin c domain 24 in the far UV range,
performed with purified, bacterially expressed proteins. Note that the wild-type protein (wt) shows the typical b-sheet secondary structure, whereas
the mutant-protein (mut) spectrum has lower amplitudes, indicating improper folding. deg p degrees; [V]MRW p mean residue weight ellipticity.
B, The same recombinant polypeptides as above were cross-linked using ethylene glycol bis(succinimidylsuccinate) (EGS). Proteins were separated
by SDS-PAGE, and the gel was stained with Coomassie Brilliant Blue. Without cross-linking (), only monomers (m) of the wild type and the
truncated mutant polypeptide are visible. Note that, on cross-linking (), the wild-type protein yields dimers (d), whereas the mutant protein yields
aggregates (a) of higher molecular mass.
subsequently, the disorder was referred to as “LGMD1F”
(MIM 608423) and was mapped to chromosome 7q32,
which includes the FLNC locus. However, in this family,
FLNC was excluded as a candidate gene (Palenzuela et
al. 2003). In the Spanish family, skeletal-muscle weak-
ness, predominantly involving the pelvic and shoulder
girdle, started between the ages of 1 year and 58 years,
whereas, in the German family, no patient with a juvenile-
onset form was observed. In the Spanish family, the his-
tochemical and immunohistochemical findings were com-
patible with LGMD; desmin immunostaining was not
reported. In contrast, the massive protein aggregates in
the German family clearly indicated MFM. Despite sub-
stantial overlap in the clinical phenotype, patients in the
German family are distinct—not only genetically but
also morphologically—from patients with LGMD1F. Be-
cause of the protein defect, we suggest classification of
the disease found in the German family as “autosomal
dominant filaminopathy,” a novel form of MFM.
Filamins are a family of actin-binding proteins involved
in reshaping the actin cytoskeleton and its associated
structures (Stossel et al. 2001; van der Flier and Son-
nenberg 2001). Actin binding is conferred by a pair of
amino-terminal CH domains. For their actin filament–
bundling and cross-linking activities, the filamins depend
on their C-terminal region—more specifically, the im-
munoglobulin-like domain 24, which is responsible for
dimer formation (Himmel et al. 2003). Furthermore, fi-
lamins interact with a plethora of cellular proteins of
great functional diversity, indicating that they are multi-
functional signaling adapter proteins (van der Flier and
Sonnenberg 2001). Although mutations in the ubiqui-
tously expressed genes encoding filamin a (Fox et al.
1998; Robertson et al. 2003) and filamin b (Krakow et
al. 2004) are causative for a strikingly wide range of
human diseases (Feng and Walsh 2004), up to the pre-
sent, no disease-causing mutations had been found in
FLNC, the gene encoding the muscle-specific filamin iso-
form. Its up-regulation during initial stages of myocyte
differentiation, its localization predominantly at the pe-
riphery of Z-disks (van der Ven et al. 2000a), and its
direct interaction with myotilin (van der Ven et al.
2000b) imply an important role for this filamin isoform
during myofibrillogenesis. Since filamin c also binds g-
and d-sarcoglycan at the sarcolemma (Thompson et al.
2000), it was hypothesized that filamin c is involved in
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signaling pathways from the sarcolemma to the myofi-
bril (Thompson et al. 2000; van der Ven et al. 2000b).
The W2710X mutation in the reported family with
MFM leads to a truncation of the filamin c immuno-
globulin domain that is responsible for dimerization
(Himmel et al. 2003). To assess the pathogenic potential
of the mutation, we examined its effects on the second-
ary structure of the mutant domain 24 and on its ability
to dimerize. cDNA fragments encoding the wild-type
and mutant domain 24 were cloned in pET23-T7 (Ob-
ermann et al. 1998), and recombinant proteins were ex-
pressed in and purified from Escherichia coli BL21-Co-
donPlus-RP cells by use of standard procedures (Himmel
et al. 2003). Circular dichroism spectra were recorded
from both proteins on a Jasco J-715 spectropolarimeter.
Whereas analysis of the wild-type domain resulted in the
typical b-sheet secondary structure that was previously
reported for this domain (Himmel et al. 2003; Pudas et
al. 2005), analysis of the truncated, mutated domain re-
sulted in significantly lower signals, suggesting improper
folding (fig. 3A).
We next examined dimerization of mutant filamin c
by chemical cross-linking experiments, essentially using
previously established conditions for the wild-type pro-
tein (Himmel et al. 2003), except that PBS was used
instead of cross-linking buffer. Whereas the dimerization
of the wild-type variant was reproduced under these con-
ditions, cross-linking of the truncated domain 24 did
not result in the detection of dimers. Instead, high–mo-
lecular mass aggregates of the mutated filamin fragment
were observed on the SDS-polyacrylamide gel (fig. 3B)
and on immunoblots (not shown). Although the precise
structural changes that occur in the mutated filamin c
are currently unknown, the formation of aggregates in
the cross-linking assay and the tendency to precipitate
in solution (not shown) imply a weaker stability of mu-
tated filamin c in comparison with the wild-type protein
and indicate a strong tendency for uncontrolled aggre-
gation rather than defined dimerization.
We have provided evidence of an altered distribution
of myotilin and the dystrophin-sarcoglycan complex in
affected individuals. We hypothesize that the fine balance
of filamin c and its binding partners in both the Z-disk
and the cell membrane may be disturbed. Therefore, de-
fects in this protein may weaken myofibrils and, at the
same time, destabilize the muscle cell membrane. This
may ultimately result in clinical and molecular features
resembling both MFM and LGMD.
In summary, we describe here the first disease-related
mutation within the FLNC gene and also the first muta-
tion in a dimerization domain in the filamin family. The
mutation results in the inability of the mutant protein
to dimerize and leads to the generation of large filamin
c–containing aggregates within the skeletal-muscle fibers.
Biochemical experiments provide an explanation for this
observation and show that dimer formation is essential
for the biological function of filamin.
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